Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04800471 · ClinicalTrials.gov registry record · NA
Improving Glycemic Control in DM2 Patients in the Ambulatory Setting
A NA study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT04800471: Completed NA study, sponsored by University of Maryland, Baltimore.
NCT04800471 is a NA study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04800471, a NA study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
More than 10.5% of the US population has diabetes mellitus. The objective of this pilot study is to evaluate whether smart insulin pens combined with CGM devices can improve glucose control in patients with type 2 diabetes (T2D)
Primary Outcome
HbA1C test is a blood test that shows your average level of blood glucose, also called blood sugar, over the past three months.
Interventions
- DEVICE Smart insulin pens and CGM
- OTHER Point of Care Glucose Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-08-16 |
| Est. Completion | 2024-07-09 |
| Phase | NA |
What the finished NCT04800471 record still lists
NCT04800471 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Smart insulin pens and CGM is the first listed.
NCT04800471 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04800471 about?
NCT04800471 is a clinical study titled "Improving Glycemic Control in DM2 Patients in the Ambulatory Setting". More than 10.5% of the US population has diabetes mellitus. The objective of this pilot study is to evaluate whether smart insulin pens combined with CGM devices can improve glucose control in patients with type 2 diabetes (T2D)
What is the current status of trial NCT04800471?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-08-16. Estimated completion is 2024-07-09.
What interventions are being tested in trial NCT04800471?
The interventions under investigation include: Smart insulin pens and CGM (DEVICE), Point of Care Glucose Group (OTHER).
Who is sponsoring clinical trial NCT04800471?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04800471's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI